Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved Foundayo, orforglipron, marking the first new molecular entity approved under the Commissioner's National Priority Voucher pilot.
The agency said the decision came 50 days after filing and 294 days before the application's PDUFA date.
The approval is both a medicine story and a regulatory-process story: FDA is testing whether priority mechanisms can compress review timelines without lowering evidence standards.
Why It Matters
Faster review pathways can reshape drug-development economics, especially if they become repeatable for high-priority therapies.
What to Watch
Watch post-approval safety, payer uptake and whether the CNPV pilot expands or narrows after early cases.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAObesityDrug ReviewPriority Voucher